骨系統疾患の市場規模、シェア、動向分析レポート：タイプ別、治療別、症状別、地域別、セグメント別予測、2025年～2030年

骨系統疾患市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の骨系統疾患市場規模は2025年から2030年にかけてCAGR 2.0％を記録し、2030年までに38億5,000万米ドルに達すると予測されています。

特に小児におけるこの疾患の有病率の増加と希少疾病用医薬品の採用拡大が、市場拡大に寄与している可能性が高いです。

様々な疾患の中で軟骨無形成症は最も一般的な疾患です。国立ヒトゲノム研究所が2016年に発表した推計によると、軟骨無形成症は15,000～40,000人に1人の割合で発生するといいます。現在、軟骨無形成症に特化して承認された治療法はないが、臨床開発中の治療法が5つあります。

本疾患に起因する遺伝子異常には、FGFR3遺伝子の自然変異が含まれます。BioMarin社のVosoritideはFGFR3経路の阻害を標的としており、軟骨無形成症に対するファースト・イン・クラスの薬剤です。この薬剤は第III相臨床試験中であり、2024年に市場に参入する予定です。クレメンティア（イプセングループ）とリジェネロンは、多発性骨軟骨腫や進行性骨化性線維異形成症（FOP）などの疾患を標的とする他の市場プレイヤーです。予測期間中にこれらのパイプライン治療薬がオーファンドラッグとして承認されれば、骨系統疾患市場の成長をさらに後押しすると思われます。

医薬品は障害の遺伝的原因によって異なり、XLHや低ホスファターゼ症など、治癒可能な治療法が承認されているのは、ウルトラジェニックス・ファーマシューティカルズのCrysvitaやアレクシオン・ファーマシューティカルズのStrensiqなど、ほんの一握りです。Crysvitaは2018年にFDAの承認を受けたのに対し、Strensiqは2015年に承認を受けた。Strensiqの売上高は2015年の1,200万米ドルから2018年には4億7,510万米ドルに増加しました。これらの希少疾病用医薬品の取り込みの増加は、市場成長のシグナルです。

骨系統疾患市場レポートハイライト

• 低ホスファターゼ症（HPP）が市場を独占し、2024年には48.5%の最大売上シェアを占めました。
• 薬物療法が市場をリードし、2024年には48.5％の最大売上シェアを占めました。
• 副甲状腺障害、成長ホルモン療法、脊椎・四肢骨切り術を含む骨格奇形が市場を独占し、2024年には20.9％の最大売上シェアを占めました。
• 欧州の骨系統疾患市場は世界市場を独占し、2024年には39.4％の最大収益シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 骨系統疾患市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場 促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析

第4章 骨系統疾患市場： 疾患タイプ別ビジネス分析

• 疾患タイプの市場シェア、2024年および2030年
• 障害タイプセグメントダッシュボード
• 障害タイプ別の市場規模と予測および動向分析、2018年から2030年
• X連鎖性低リン血症（XLH）
• 低ホスファターゼ症（HPP）
• 軟骨無形成症
• 進行性骨化性線維異形成症（FOP）
• 多発性骨軟骨腫（MO）

第5章 骨系統疾患市場：治療別ビジネス分析

• 治療市場シェア、2024年と2030年
• 治療セグメントダッシュボード
• 市場規模と予測および動向分析、治療、2018年から2030年
• 薬
• 手術

第6章 骨系統疾患市場： 症状別ビジネス分析

• 症状市場シェア、2024年と2030年
• 症状セグメントダッシュボード
• 市場規模と予測および動向分析、症状別、2018～2030年
• 骨格の変形
• 歯の変形
• その他

第7章 骨系統疾患市場：地域別推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
  • ロシア
• アジア太平洋
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • 香港
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 参入企業概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル
  • BioMarin
  • Amgen Inc.
  • Merck KGaA
  • Regeneron
  • Alexion Pharmaceuticals, Inc.
  • Clementia（Ipsen Group）.
  • AstraZeneca plc.
  • Biomarin Pharmaceuticals Inc.
  • Cipla Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Skeletal Dysplasia Market, by Region, 2018 - 2030 (USD Million)
• Table 4 Global Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 5 Global Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 6 Global Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 7 North America Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
• Table 8 North America Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 9 North America Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 10 North America Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 11 U.S Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 12 U.S Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 13 U.S Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 14 Canada Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 15 Canada Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 16 Canada Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 17 Mexico Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 18 Mexico Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 19 Mexico Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 20 Europe Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
• Table 21 Europe Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 22 Europe Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 23 Europe Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 24 UK Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 25 UK Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 26 UK Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 27 Germany Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 28 Germany Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 29 Germany Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 30 France Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 31 France Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 32 France Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 33 Italy Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 34 Italy Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 35 Italy Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 36 Spain Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 37 Spain Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 38 Spain Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 39 Norway Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 40 Norway Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 41 Norway Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 42 Denmark Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 43 Denmark Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 44 Denmark Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 45 Sweden Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 46 Sweden Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 47 Sweden Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 52 Japan Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 53 Japan Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 54 Japan Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 55 China Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 56 China Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 57 China Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 58 India Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 59 India Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 60 India Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 61 Australia Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 62 Australia Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 63 Australia Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 64 South Korea Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 65 South Korea Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 66 South Korea Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 67 Thailand Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 68 Thailand Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 69 Thailand Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 70 Latin America Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
• Table 71 Latin America Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 72 Latin America Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 73 Latin America Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 74 Brazil Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 75 Brazil Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 76 Brazil Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 77 Argentina Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 78 Argentina Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 79 Argentina Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 84 South Africa Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 85 South Africa Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 86 South Africa Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 90 UAE Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 91 UAE Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 92 UAE Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
• Table 93 Kuwait Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
• Table 94 Kuwait Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
• Table 95 Kuwait Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Skeletal Dysplasia market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Segment outlook
• Fig. 10 Segment outlook
• Fig. 11 Competitive landscape
• Fig. 12 Skeletal dysplasia market dynamics
• Fig. 13 Skeletal dysplasia market: Porter's five forces analysis
• Fig. 14 Skeletal dysplasia market: PESTLE analysis
• Fig. 15 Skeletal dysplasia market: Disorder Type segment dashboard
• Fig. 16 Skeletal dysplasia market: Disorder Type market share analysis, 2024 & 2030
• Fig. 17 X-linked hypophosphatemia (XLH) market, 2018 - 2030 (USD Million)
• Fig. 18 Hypophosphatasia (HPP) market, 2018 - 2030 (USD Million)
• Fig. 19 Achondroplasia market, 2018 - 2030 (USD Million)
• Fig. 20 Fibrodysplasia ossificans progressive (FOP) market, 2018 - 2030 (USD Million)
• Fig. 21 Multiple osteochondromas (MO) market, 2018 - 2030 (USD Million)
• Fig. 22 Skeletal dysplasia market: Treatment segment dashboard
• Fig. 23 Skeletal dysplasia market: Treatment market share analysis, 2024 & 2030
• Fig. 24 Medication market, 2018 - 2030 (USD Million)
• Fig. 25 Surgery market, 2018 - 2030 (USD Million)
• Fig. 26 Skeletal dysplasia market: Symptoms segment dashboard
• Fig. 27 Skeletal dysplasia market: Symptoms market share analysis, 2024 & 2030
• Fig. 28 Skeletal deformities market, 2018 - 2030 (USD Million)
• Fig. 29 Dental deformities laboratories market, 2018 - 2030 (USD Million)
• Fig. 30 Others market, 2018 - 2030 (USD Million)
• Fig. 31 Skeletal dysplasia market revenue, by region
• Fig. 32 Regional marketplace: Key takeaways
• Fig. 33 Regional marketplace: Key takeaways
• Fig. 34 North America skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 35 U.S. country dynamics
• Fig. 36 U.S. skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 37 Canada country dynamics
• Fig. 38 Canada skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 39 Mexico country dynamics
• Fig. 40 Mexico skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 41 Europe skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 42 UK country dynamics
• Fig. 43 UK skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 44 Germany country dynamics
• Fig. 45 Germany skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 46 France country dynamics
• Fig. 47 France skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 48 Italy country dynamics
• Fig. 49 Italy skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 50 Spain country dynamics
• Fig. 51 Spain skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 52 Norway country dynamics
• Fig. 53 Norway skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 54 Sweden country dynamics
• Fig. 55 Sweden skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 56 Denmark country dynamics
• Fig. 57 Denmark skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 58 Asia Pacific skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 59 Japan country dynamics
• Fig. 60 Japan skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 61 China country dynamics
• Fig. 62 China skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 63 India country dynamics
• Fig. 64 India skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 65 Australia country dynamics
• Fig. 66 Australia skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 67 South Korea country dynamics
• Fig. 68 South Korea skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 69 Thailand country dynamics
• Fig. 70 Thailand skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 71 Latin skeletal dysplasia Dysplasia market, 2018 - 2030 (USD Million)
• Fig. 72 Brazil country dynamics
• Fig. 73 Brazil skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 74 Argentina country dynamics
• Fig. 75 Argentina skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 76 MEA Skeletal Dysplasia market, 2018 - 2030 (USD Million)
• Fig. 77 South Africa country dynamics
• Fig. 78 South Africa skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 79 Saudi Arabia country dynamics
• Fig. 80 Saudi Arabia skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 81 UAE country dynamics
• Fig. 82 UAE skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 83 Kuwait Key country dynamics
• Fig. 84 Kuwait skeletal dysplasia market, 2018 - 2030 (USD Million)
• Fig. 85 Company categorization
• Fig. 86 Company market position analysis
• Fig. 87 Strategic framework

Skeletal Dysplasia Market Growth & Trends:

The global skeletal dysplasia market size is expected to reach USD 3.85 billion by 2030, registering a CAGR of 2.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of this condition, especially in children, and growing adoption of orphan drugs are likely to contribute to the expansion of the market.

Among different disorders, achondroplasia is the most common condition. According to estimates published by the National Human Genome Research Institute in 2016, achondroplasia occurs in 1 in 15,000-40,000 live births. Although there are no current therapies approved specifically for achondroplasia, there are five therapies under clinical development.

Genetic defects attributable to the disorder include spontaneous mutations in the FGFR3 gene. Vosoritide by BioMarin targets inhibition of the FGFR3 pathway and presents a first-in-class drug for achondroplasia. The drug is in phase III clinical trial and is expected to enter the market in 2024. Clementia (Ipsen Group) and Regeneron are other market players targeting disorders such as multiple osteochondromas and fibrodysplasia ossificans progressiva (FOP). Approval of these pipeline therapies with orphan drug status during the forecast period will further support skeletal dysplasia market growth.

The medicines vary depending on the genetic cause of the disorder and only a handful of the disorders, such as XLH and hypophosphatasia, have approved curative therapies, including Ultragenyx Pharmaceuticals' Crysvita and Alexion Pharmaceuticals' Strensiq, respectively. Crysvita received FDA approval in 2018 whereas Strensiq received approval in 2015. The sales of Strensiq increased from USD 12.0 million in 2015 to USD 475.1 million in 2018. Higher uptake of these orphan drugs signal growth of the market.

Skeletal Dysplasia Market Report Highlights:

• Hypophosphatasia (HPP) dominated the market and accounted for the largest revenue share of 48.5% in 2024 attributed to the increasing awareness and improved diagnostic capabilities, leading to more frequent diagnoses of this rare genetic disorder.
• Medications led the market and accounted for the largest revenue share of 48.5% in 2024 attributed to the advancements in drug development and increased awareness of skeletal dysplasias.
• Skeletal deformities, including parathyroid disorders, growth hormone therapies, and spinal and limb osteotomies, dominated the market and accounted for the largest revenue share of 20.9% in 2024.
• Europe skeletal dysplasia market dominated the global market and accounted for the largest revenue share of 39.4% in 2024 attributed to heightened awareness and improved diagnostic capabilities.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disorder Type
  • 1.2.2. Treatment
  • 1.2.3. Symptoms
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Skeletal Dysplasia Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Skeletal Dysplasia Market: Disorder Type Business Analysis

• 4.1. Disorder Type Market Share, 2024 & 2030
• 4.2. Disorder Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Disorder Type, 2018 to 2030 (USD Million)
• 4.4. X-linked Hypophosphatemia (XLH)
  • 4.4.1. X-linked Hypophosphatemia (XLH) Market, 2018 - 2030 (USD Million)
• 4.5. Hypophosphatasia (HPP)
  • 4.5.1. Hypophosphatasia (HPP) Market, 2018 - 2030 (USD Million)
• 4.6. Achondroplasia
  • 4.6.1. Achondroplasia Market, 2018 - 2030 (USD Million)
• 4.7. Fibrodysplasia Ossificans Progressive (FOP)
  • 4.7.1. Fibrodysplasia Ossificans Progressive (FOP) Market, 2018 - 2030 (USD Million)
• 4.8. Multiple Osteochondromas (MO)
  • 4.8.1. Multiple Osteochondromas (MO) Market, 2018 - 2030 (USD Million)

Chapter 5. Skeletal Dysplasia Market: Treatment Business Analysis

• 5.1. Treatment Market Share, 2024 & 2030
• 5.2. Treatment Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 5.4. Medication
  • 5.4.1. Medication Market, 2018 - 2030 (USD Million)
• 5.5. Surgery
  • 5.5.1. Surgery Market, 2018 - 2030 (USD Million)

Chapter 6. Skeletal Dysplasia Market: Symptoms Business Analysis

• 6.1. Symptoms Market Share, 2024 & 2030
• 6.2. Symptoms Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Symptoms, 2018 to 2030 (USD Million)
• 6.4. Skeletal Deformities
  • 6.4.1. Skeletal Deformities Market, 2018 - 2030 (USD Million)
• 6.5. Dental Deformities
  • 6.5.1. Dental Deformities Market, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Skeletal Dysplasia Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Skeletal Dysplasia Market Estimates and Forecastsasts, 2018 - 2030 (USD Million)
  • 7.5.10. Russia
    • 7.5.10.1. Key Country Dynamics
    • 7.5.10.2. Regulatory Framework
    • 7.5.10.3. Competitive Insights
    • 7.5.10.4. Russia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Hong Kong
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Hong Kong Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.8. Thailand
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Regulatory Framework
    • 7.6.8.3. Competitive Insights
    • 7.6.8.4. Thailand Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. BioMarin
    • 8.5.1.1. Company Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Amgen Inc.
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Merck KGaA
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Regeneron
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Alexion Pharmaceuticals, Inc.
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Clementia (Ipsen Group).
    • 8.5.6.1. Company Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. AstraZeneca plc.
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Biomarin Pharmaceuticals Inc.
    • 8.5.8.1. Company Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Cipla Ltd.
    • 8.5.9.1. Company Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Eli Lilly and Company
    • 8.5.10.1. Company Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. F. Hoffmann-La Roche AG.
    • 8.5.11.1. Company Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. Pfizer, Inc.
    • 8.5.12.1. Company Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic Initiatives
  • 8.5.13. Teva Pharmaceutical Industries Ltd.
    • 8.5.13.1. Company Overview
    • 8.5.13.2. Financial Performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic Initiatives